

### At a Glance

- Active since 2004
- Spin-out of the Max Planck Institute of Psychiatry

### Management Team

- Manfred Rüdiger, CEO
- Luc St-Onge, CBO
- Michael Bös, CSO

### Supervisory Board

- Joachim Rothe, Chairman
- Domenico Valerio, Vice-Chairman
- Stefan Herr
- Paul Sekhri
- Wolfgang Wurst

### Investors

- Life Sciences Partners
- Aescap Venture
- EMBL Technology Fund
- KfW
- BayernKapital

### Contact:

Luc St-Onge, CBO  
 Affectis Pharmaceuticals AG  
 Fraunhoferstrasse 13  
 D-82152 Martinsried  
 Germany  
 Tel. +49 (0)89 893 2811 100  
 Fax. +49 (0)89 893 2811 111  
 info@affectis.com  
 www.affectis.com



### Novel Drugs for the Treatment of Neurodegenerative and Neuroinflammatory Diseases

Affectis is a pharmaceuticals company developing novel drugs for the treatment of neurodegenerative and neuroinflammatory diseases.

Affectis' unique capabilities in drug discovery and medicinal chemistry allow the company to develop drugs with innovative mechanisms of action based on pioneering findings in the field of P2X7 receptors, neurodegeneration and neuroinflammation.

Affectis has successfully partnered several of its programs which carry the promise of bringing to market entirely new classes of drugs that would address and satisfy unmet needs.

### Pipeline

| Program               | Indication                             | Mechanism of Action                | Stage                   | Partner   |
|-----------------------|--|------------------------------------|-------------------------|---|
| <b>AFC-5128</b>       | Neuropathic Pain<br>Multiple Sclerosis | Oral CNS-Penetrant P2X7 Antagonist | Preclinical             |   |
| <b>P2X7 compounds</b> | Neurodegenerative Diseases             | Oral Compounds Targeting P2X7      | Discovery & Preclinical |  |
| <b>AFC-5278</b>       | Osteoporosis                           | Oral P2X7 antagonist               | Discovery               |   |
| <b>AFC-08</b>         | Depression                             | TMEFF2 Monoclonal Antibody         | Discovery               |  |

### In-house Programs

AFC-5128 is a potent CNS-penetrant oral P2X7 antagonist being developed for the treatment of neuropathic pain and multiple sclerosis. A key competitive advantage of AFC-5128 is its ability to cross the blood-brain barrier and target P2X7 expressing cells such as glia cells which have been linked to neurodegenerative processes. AFC-5128 is currently in preclinical development with IND filing and initiation of phase I studies planned for 2012.

Affectis is also developing AFC-5278, an oral non-CNS penetrant P2X7 antagonist for the treatment of osteoporosis. Studies suggest that P2X7 controls certain aspects of osteoclast cells involved in progressive bone loss leading to osteoporosis. Inhibition of P2X7 by AFC-5278 aims to reduce osteoclast activity, prevent bone loss and offer a new therapeutic approach for the treatment of osteoporosis.

### Partnered Programs

Merck Serono has entered into a partnership with Affectis to develop and commercialize certain oral compounds targeting P2X7 for the treatment of neurodegenerative diseases.

Affectis has also partnered its AFC-08 program to Phenoquest AG. AFC-08, a monoclonal antibody targeting the brain membrane protein TMEFF2 for potential prophylactic use and relapse prevention in depression.

### Business Model and Collaborations

Affectis develops proprietary drug candidates from discovery to clinical stage and will partner or license its programs at late development stage to accelerate development and commercialisation of its candidates.